DexCom, Inc. vs Oklo Inc — how do they compare? DexCom, Inc. trades at $90.57 (market cap $33.79B), while Oklo Inc trades at $45.77 (market cap $8.74B). The key difference: DexCom, Inc. is far larger — about 3.9× Oklo Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, Oklo Inc nearer its low. Which is the better fit depends on your goals.
| DXCM | OKLO | |
|---|---|---|
Market Cap | $33.79B | $8.74B |
Sector | Health | Technology |
52-Week High | $89.53 | $174.14 |
52-Week Low | $54.84 | $36.84 |
Enterprise Value | $33.24B | $6.28B |
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $90.23, up 2.94% today and near its 52-week high, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating EPS estimates with $0.70 versus $0.61 expected, and raised full-year guidance. Revenue growth remains robust at 13% year-over-year, supported by G7 system adoption and international expansion. Profit margins improved, with net income margin reaching 20.12% in 2025. Analyst sentiment is overwhelmingly positive, with 80% buy ratings.
The outlook for DXCM is favorable due to sustained demand for continuous glucose monitors and strategic initiatives like 'Road to 100'. Key risks include competitive pressures, regulatory scrutiny, and valuation multiples above industry averages. The stock's current price is slightly above the consensus target of $88.65, suggesting near-term consolidation may occur before further upside.
OKLO trades at $45.71, up 2.74% with a bullish technical outlook despite recent volatility. The company reported its first revenue of $1.2 million in Q2 2026 but continues to post significant losses (-$105.66M net income in 2025) with negative margins. Analyst consensus remains strongly bullish with a $77.07 price target, though CEO share sales and high cash burn present near-term concerns.
While OKLO shows promising nuclear technology development with recent milestones, investors face substantial execution risks amid widening losses and negative cash flow. The stock offers high growth potential in the emerging nuclear energy sector but requires careful risk management given the pre-profitability stage and volatile price action.
Trailing returns across standard periods
Latest headlines on both assets
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →Oklo Inc. is a company focused on developing and commercializing advanced fission power plants. The company specializes in micro-reactor technology, specifically the Aurora design, which uses advanced fuel to produce reliable, clean, and cost-competitive power. Oklo aims to provide scalable, on-site power solutions to various customers, including remote communities, industrial facilities, and government entities, positioning itself as an innovator in the next generation of nuclear energy.
Read more on OKLO →